We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.46%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.24%
AUM
$17B
AUM Growth
+$1.34B
(+8.6%)
Cap. Flow
-$377M
Cap. Flow
% of AUM
-2.22%
Top 10 Holdings %
Top 10 Hldgs %
15.59%
Holding
389
New
43
Increased
82
Reduced
143
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$204M |
| 2 |
AbbVie
ABBV
|
+$141M |
| 3 |
TYC
TYCO INTL PLC COM SHS (IRL)
TYC
|
+$130M |
| 4 |
Caterpillar
CAT
|
+$125M |
| 5 |
Johnson Controls International
JCI
|
+$90.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPHM
VIROPHARMA INC
VPHM
|
+$188M |
| 2 |
Merck
MRK
|
+$155M |
| 3 |
Apple
AAPL
|
+$155M |
| 4 |
CTXS
Citrix Systems Inc
CTXS
|
+$131M |
| 5 |
Bread Financial
BFH
|
+$96.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.01% |
| 2 | Industrials | 15.63% |
| 3 | Consumer Discretionary | 14.7% |
| 4 | Technology | 8.94% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alphabet (Google) Class C
GOOG
$3.9T
| $397M | 2.34% |
14,237,005
-156,986
| -1% | -$3.97M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $371M | 2.18% |
4,388,904
-122,954
| -3% | -$9.73M |
|
|
3
Apple
AAPL
$4.89T
| $325M | 1.91% |
16,214,744
-8,191,316
| -34% | -$155M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $268M | 1.58% |
1,595,505
+214,643
| +16% | +$33.6M |
|
5
Visa
V
$677B
| $231M | 1.36% |
4,152,984
-42,840
| -1% | -$2.16M |
|
6
Thermo Fisher Scientific
TMO
$211B
| $225M | 1.33% |
2,023,919
-14,831
| -0.7% | -$1.47M |
|
|
ANDV
7
DELISTED
Andeavor
ANDV
| $224M | 1.32% |
3,833,016
-512,403
| -12% | -$26.7M |
|
|
8
Teva Pharmaceuticals
TEVA
$35.9B
| $207M | 1.22% |
+5,174,039
| New | +$204M |
|
9
Booking.com
BKNG
$138B
| $203M | 1.2% |
4,375,725
-69,425
| -2% | -$3.09M |
|
10
Ametek
AME
$55.5B
| $195M | 1.15% |
3,700,752
+1,123,108
| +44% | +$54.2M |
|
11
Bristol-Myers Squibb
BMY
$127B
| $194M | 1.14% |
3,653,936
-776,929
| -18% | -$39.6M |
|
12
RTX Corp
RTX
$287B
| $193M | 1.14% |
2,697,761
-32,057
| -1% | -$2.18M |
|
|
CBST
13
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $186M | 1.1% |
2,703,519
+878,385
| +48% | +$56.9M |
|
14
Salesforce
CRM
$134B
| $184M | 1.08% |
3,338,196
-35,031
| -1% | -$1.87M |
|
15
Cooper Companies
COO
$13.7B
| $179M | 1.05% |
5,777,780
-69,212
| -1% | -$2.21M |
|
16
Walt Disney
DIS
$165B
| $177M | 1.04% |
2,311,866
-13,186
| -0.6% | -$913K |
|
17
NOV
NOV
$7.45B
| $176M | 1.03% |
2,449,197
-25,896
| -1% | -$1.88M |
|
18
American International
AIG
$41.9B
| $175M | 1.03% |
3,418,269
-30,491
| -0.9% | -$1.52M |
|
19
Amazon
AMZN
$2.5T
| $168M | 0.99% |
8,446,440
-90,700
| -1% | -$1.63M |
|
20
Mondelez International
MDLZ
$77.7B
| $167M | 0.98% |
4,724,413
-44,903
| -0.9% | -$1.49M |
|
|
21
Bread Financial
BFH
$4.21B
| $165M | 0.97% |
787,177
-507,048
| -39% | -$96.8M |
|
22
Costco
COST
$415B
| $163M | 0.96% |
1,373,134
-15,058
| -1% | -$1.8M |
|
23
Valero Energy
VLO
$89.8B
| $163M | 0.96% |
3,225,498
-1,024,494
| -24% | -$43.2M |
|
24
Hershey
HSY
$35.4B
| $162M | 0.95% |
1,665,477
-16,680
| -1% | -$1.6M |
|
25
Cardinal Health
CAH
$53.4B
| $162M | 0.95% |
2,420,105
-785,355
| -25% | -$48M |
|
Similar funds
OAG
JG
CHP
SAM
Westfield Capital Management's Q4 2013 Portfolio in Review
As of Q4 2013, Westfield Capital Management held 389 positions worth $17B, up 8.6% from $15.6B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Westfield Capital Management's Q4 2013 filing shows 43 new, 82 increased, 143 reduced and 65 closed positions. Its largest new stake was Teva Pharmaceuticals: 5,174,039 shares worth $207M. The largest sale was VIROPHARMA INC, an estimated $188M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.
- Westfield Capital Management's largest Q4 2013 buy was Teva Pharmaceuticals: 5,174,039 shares worth $207M.
- Westfield Capital Management added most to AbbVie in Q4 2013, an estimated $141M increase.
- Westfield Capital Management's biggest Q4 2013 reduction was VIROPHARMA INC, cutting an estimated $188M.
- Westfield Capital Management fully exited Citrix Systems Inc in Q4 2013, selling an estimated $131M.
- Westfield Capital Management's ten largest holdings make up 16% of its $17B portfolio in Q4 2013.
- Westfield Capital Management opened 43 new positions and closed 65 in Q4 2013.
- Westfield Capital Management's portfolio value rose 8.6% quarter-over-quarter to $17B.
Based on Westfield Capital Management's 13F filing for Q4 2013, filed 7 Feb 2014.